Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13970167 | 1.00 | SLC6A9 (0.48) | SLC6A9CTSS | |
| SCHEMBL8084955 | 0.90 | SLC6A9 (0.60) | SLC6A9CTSS | |
| SCHEMBL8083778 | 0.90 | SLC6A9 (0.60) | SLC6A9CTSS | |
| SCHEMBL13970181 | 0.90 | SLC6A9 (0.60) | SLC6A9CTSS | |
| SCHEMBL4188979 | 0.81 | SLC6A9 (0.66) | SLC6A9CTSS | |
| SCHEMBL13949282 | 0.81 | SLC6A9 (0.66) | SLC6A9CTSS | |
| SCHEMBL8087275 | 0.81 | SLC6A9 (0.57) | SLC6A9 | |
| SCHEMBL8088699 | 0.81 | SLC6A9 (0.56) | SLC6A9 | |
| SCHEMBL8083920 | 0.80 | SLC6A9 (0.64) | SLC6A9 | |
| SCHEMBL786934 | 0.79 | SLC6A9 (0.64) | SLC6A9CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030033-A1 | Novel Compounds 894 | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013535-A1 | 2-AZABICYCLO(2.2.2)OCTANE DERIVATIVES AS MODULATORS OF THE GLYCINE TRANSPORTER I RECEPTOR | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030033-A1 | Novel Compounds 894 | AZI2, TPMT, AMPD2 | SLC6A9 4382/4885CTSS 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.